Samantha Semenkow
Stock Analyst at Citi
(3.11)
# 2,599
Out of 4,604 analysts
203
Total ratings
49.7%
Success rate
2.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $142 → $143 | $108.85 | +31.37% | 3 | Aug 5, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | $46 → $52 | $31.87 | +63.16% | 5 | Jul 31, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | $24 → $19 | $5.99 | +217.20% | 5 | Jul 31, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $52 | $11.50 | +352.17% | 10 | Jul 31, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,152 → $1,203 | $869.39 | +38.37% | 20 | Jul 24, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $73.54 | +105.33% | 10 | Jul 21, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $14 | $4.21 | +232.94% | 19 | Jun 30, 2026 | |
| IMVT Immunovant | Maintained: Buy | $57 → $61 | $39.81 | +53.23% | 16 | Jun 30, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $11 | $3.79 | +190.62% | 2 | Jun 15, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $33 | $17.65 | +86.97% | 2 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $42 | $35.25 | +19.15% | 5 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 | $28.11 | +141.91% | 15 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $64 → $97 | $103.80 | -6.55% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 | $1.96 | +104.08% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $17 | $13.83 | +22.92% | 6 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.12 | +252.56% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $18.08 | -66.81% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $51.30 | +94.93% | 5 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.40 | +252.94% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4.25 | $3.01 | +41.20% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.79 | +258.42% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $5 | $2.85 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $24.70 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.7 → $0.75 | $0.0001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $18.52 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $7 | $5.01 | n/a | 2 | Jul 21, 2021 |
Rhythm Pharmaceuticals
Aug 5, 2026
Maintained: Buy
Price Target: $142 → $143
Current: $108.85
Upside: +31.37%
Agios Pharmaceuticals
Jul 31, 2026
Maintained: Buy
Price Target: $46 → $52
Current: $31.87
Upside: +63.16%
Wave Life Sciences
Jul 31, 2026
Maintained: Buy
Price Target: $24 → $19
Current: $5.99
Upside: +217.20%
BioAge Labs
Jul 31, 2026
Maintained: Buy
Price Target: $52
Current: $11.50
Upside: +352.17%
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: $1,152 → $1,203
Current: $869.39
Upside: +38.37%
Nektar Therapeutics
Jul 21, 2026
Maintained: Buy
Price Target: $151
Current: $73.54
Upside: +105.33%
Larimar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $14
Current: $4.21
Upside: +232.94%
Immunovant
Jun 30, 2026
Maintained: Buy
Price Target: $57 → $61
Current: $39.81
Upside: +53.23%
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $3.79
Upside: +190.62%
Cullinan Therapeutics
Jun 10, 2026
Reiterated: Buy
Price Target: $33
Current: $17.65
Upside: +86.97%
May 21, 2026
Reiterated: Buy
Price Target: $35 → $42
Current: $35.25
Upside: +19.15%
May 13, 2026
Maintained: Buy
Price Target: $68
Current: $28.11
Upside: +141.91%
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $103.80
Upside: -6.55%
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $1.96
Upside: +104.08%
Apr 2, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $13.83
Upside: +22.92%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.12
Upside: +252.56%
Mar 20, 2026
Maintained: Sell
Price Target: $6
Current: $18.08
Upside: -66.81%
Mar 16, 2026
Reiterated: Buy
Price Target: $100
Current: $51.30
Upside: +94.93%
Mar 4, 2026
Maintained: Buy
Price Target: $12
Current: $3.40
Upside: +252.94%
Nov 11, 2025
Maintained: Hold
Price Target: $5 → $4.25
Current: $3.01
Upside: +41.20%
Oct 10, 2025
Reiterated: Buy
Price Target: $10
Current: $2.79
Upside: +258.42%
Mar 6, 2025
Maintained: Buy
Price Target: $15 → $5
Current: $2.85
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $24.70
Upside: n/a
May 18, 2023
Maintained: Hold
Price Target: $1.7 → $0.75
Current: $0.0001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $18.52
Upside: n/a
Jul 21, 2021
Maintained: Buy
Price Target: $16 → $7
Current: $5.01
Upside: n/a